Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.

Authors : Bines J, Clark E, Barton C, Restuccia E, Procter M, Sonnenblick A, Fumagalli D, Parlier D, Arahmani A, Baselga J, Viale G, Reaby LL, Frank E, Gelber Rd, Piccart-Gebhart M, Jackisch C, Petersen JA
Year : 2021
Journal : Br J Cancer
Volume : 125
Pages : 38-47

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

Authors : Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber Rd, Piccart-Gebhart M
Year : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 287-296

Overcoming Barriers to Clinical Trials Cooperation: The Breast International Group Example.

Authors : Piccart-Gebhart M, Goulioti T, Straehle C, Cameron D
Year : 2021
Journal : Am Soc Clin Oncol Educ Book
Volume : 41
Pages : 1-9

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

Authors : Piccart-Gebhart M, van t Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT
Year : 2021
Journal : Lancet Oncol
Volume : 22
Pages : 476-488

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Authors : Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada A, Santoro A, Piccart-Gebhart M, de Azambuja E
Year : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 76-91

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.

Authors : Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M, de Azambuja E
Year : 2021
Journal : Eur J Clin Invest
Pages : e13535

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.

Authors : Conforti F, Pala L, Pagan E, Rocco EG, Bagnardi V, Montagna E, Peruzzotti G, De Pas T, Fumagalli C, Pileggi S, Pesenti C, Marchini S, Corso G, Marchio C, Sapino A, Graffeo R, Collet L, Aftimos P, Sotiriou C, Piccart-Gebhart M, Gelber Rd, Viale G, Colleoni M, Goldhirsch A
Year : 2021
Journal : Breast
Volume : 59
Pages : 94-101

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.

Authors : Agostinetto E, Rediti M, Piccart-Gebhart M, Fimereli D, Debien V, Aftimos P, Sotiriou C, de Azambuja E
Year : 2021
Journal : Cancers (Basel)
Volume : 13

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.

Authors : Jackisch C, Cortazar P, Geyer CE Jr, Gianni L, Gligorov J, Machackova Z, Perez EA, Schneeweiss A, Tolaney SM, Untch M, Wardley A, Piccart-Gebhart M
Year : 2021
Journal : Cancer Treat Rev
Volume : 99
Pages : 102229

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.

Authors : Piccart-Gebhart M, Kalinsky K, Gray R, Barlow WE, Poncet C, Cardoso F, Winer E, Sparano J
Year : 2021
Journal : Ann Oncol
Volume : 32
Pages : 1077-1082

Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.

Authors : Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber Rd, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart-Gebhart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, Mcfadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr
Year : 2021
Journal : N Engl J Med
Volume : 384
Pages : 2394-2405

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Authors : Piccart-Gebhart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber Rd, Viale G, Thomssen C
Year : 2021
Journal : J Clin Oncol
Volume : 39
Pages : 1448-1457

Flexible care in breast cancer.

Authors : Wardley A, Canon JL, Elsten L, Peña Murillo C, Badovinac Crnjevic T, Fredriksson J, Piccart-Gebhart M
Year : 2021
Journal : ESMO Open
Volume : 6
Pages : 100007

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Year : 2021
Journal : Breast Cancer Res Treat
Volume : 185
Pages : 107-116

Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.

Authors : Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, de Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart-Gebhart M, Azambuja E
Year : 2021
Journal : J Natl Cancer Inst
Volume : 113
Pages : 462-470

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients.

Authors : Bohlok A, Vermeulen P, Leduc S, Latacz E, Botzenhart L, Richard F, De Schepper M, Geukens T, Lucidi V, Ignatiadis M, Aftimos P, Sotiriou C, Piccart-Gebhart M, Hendlisz A, Van Laere S, Dirix L, Noël JC, Biganzoli E, Larsimont D, Desmedt C, Donckier V
Year : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pages : 64

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial.

Authors : de Angelis C, Ignatiadis M, Piccart-Gebhart M
Year : 2020
Journal : Ann Transl Med
Volume : 8
Pages : 1338

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.

Authors : Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart-Gebhart M, Sotiriou C, González-Suárez E
Year : 2020
Journal : Nat Commun
Volume : 11
Pages : 6335

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.

Authors : Lambertini M, Agbor-Tarh D, Metzger-Filho O, Ponde NF, Poggio F, Hilbers FS, Korde LA, Chumsri S, Werner O, Del Mastro L, Caparica R, Moebus V, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.

Authors : Retèl VP, Byng D, Linn SC, Koffijberg H, Rutgers EJ, Cardoso F, Piccart-Gebhart M, Poncet C, Vant Veer LJ, van Harten WH
Year : 2020
Journal : Eur J Cancer
Volume : 137
Pages : 193-203